Shares of Silk Road Medical Inc (NASDAQ:SILK) have received an average broker rating score of 1.50 (Buy) from the four brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and three have issued a strong buy rating on the company.

Analysts have set a twelve-month consensus price objective of $44.00 for the company and are expecting that the company will post ($0.28) EPS for the current quarter, according to Zacks. Zacks has also given Silk Road Medical an industry rank of 106 out of 256 based on the ratings given to its competitors.

A number of equities research analysts recently weighed in on the stock. BMO Capital Markets assumed coverage on shares of Silk Road Medical in a research note on Monday, April 29th. They issued an “outperform” rating and a $40.01 target price on the stock. Bank of America assumed coverage on shares of Silk Road Medical in a research note on Monday, April 29th. They issued a “neutral” rating and a $43.00 target price on the stock. They noted that the move was a valuation call. Stifel Nicolaus assumed coverage on shares of Silk Road Medical in a research note on Monday, April 29th. They issued a “buy” rating and a $44.00 target price on the stock. Finally, JPMorgan Chase & Co. assumed coverage on shares of Silk Road Medical in a research note on Monday, April 29th. They issued an “overweight” rating and a $45.00 target price on the stock.

In related news, major shareholder X Finance L.P. Wp sold 900,000 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $20.00, for a total value of $18,000,000.00. The sale was disclosed in a filing with the SEC, which is available through this link.

Shares of SILK opened at $45.06 on Thursday. Silk Road Medical has a 1-year low of $30.87 and a 1-year high of $49.55.

Silk Road Medical Company Profile

Silk Road Medical, Inc operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.

See Also: Price to Earnings Ratio (PE) Basics

Get a free copy of the Zacks research report on Silk Road Medical (SILK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.